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High-sensitivity C-reactive protein in high-grade
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carotid plaque
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Objectives: Increasing evidence points to the inflammatory character of atherosclerosis, and several parameters of
inflammation have been proposed as cardiovascular risk markers. We analyzed associations among serum high-sensitivity
C-reactive protein (hs-CRP) concentrations, carotid plaque structure, and immunocytology, and neurologic symptoms in
patients with high-grade carotid stenosis.
Methods: This was a cross-sectional study in a referral center and institutional practice in hospitalized patients. The study
included 62 patients with greater than 70% carotid stenosis treated surgically; 58% of patients had symptoms, and 42% did
not. Serum hs-CRP concentrations were determined 48 hours before surgery; levels greater than 10 mg/L were
considered pathologic. Histopathologic analysis (stable or unstable) and immunohistochemistry (macrophage count, T
lymphocytes, activated T lymphocytes) were carried out on the atherosclerotic plaques.
Results: Median hs-CRP values were 7.6 mg/L (range, 0-165 mg/L). Median hs-CRP concentrations were higher in
patients with unstable plaque (53.2%) than in patients with stable plaque (46.7%): 27.1 mg/L (range, 1.8-165 mg/L)
versus 4.1 mg/L (range, 0.3-56 mg/L) (P < .001). Among patients with symptomatic disease, 81% had CRP
concentrations significantly higher than CRP concentrations in patients with asymptomatic disease (P < .001). A
statistically significant association was found between hs-CRP levels and the presence of macrophages (Spearman rank
correlation [], 0.61, P < .001) and T lymphocytes in the plaque (Spearman rank correlation [], 0.52, P < .001). At
logistic regression analysis, neurologic event and macrophages in the plaque were independently associated with unstable
plaque.
Conclusions: Increased hs-CRP levels may be related to the presence of macrophages and T lymphocytes in plaque, which
is associated with the phenomena of instability that can lead to development of an ischemic event. Thus determination of
circulating hs-CRP levels may be a useful additional marker of risk in patients with high-grade carotid stenosis. (J Vasc
Surg 2003;38:1018-24.)
Research on cell processes during the phases of athero-
sclerosis has demonstrated the existence of a specialized
form of chronic inflammatory response.1 In histopatholog-
ic2 and immunohistochemical3 studies of atherosclerotic
plaque, the presence of cells related to cellular immunity
(macrophages, T lymphocytes, activated T lymphocytes)
have been associated with unstable plaque.
In atherosclerosis, as in other diseases implicating an
inflammatory response, the cytokines increase circulating
concentrations of acute-phase reactants (markers of active
inflammation) such as fibrinogen, C-reactive protein
(CRP), amyloid A protein, sialic acid, and ceruloplasmin.
Large epidemiologic studies have related the appearance of
cardiovascular events with elevated fibrinogen4,5 and serum
amyloid A,6,7 but the acute-phase reactant that seems to
generate greatest interest is CRP. The exact role of CRP in
the inflammatory process is uncertain, but it is suggested to
have an important function, because it reacts with cell
surface receptors, facilitating phenomena of opsonization
and phagocytosis. CRP activates the classic complement
pathway, binding to chromatin fragments, inhibiting the
growth and metastatic dissemination of tumor cells, and
modulating polymorphonuclear cell functions.8 Several
studies have demonstrated that elevated CRP concentra-
tion is an independent prognostic factor in patients with
ischemic heart disease (acute coronary syndromes, unstable
angina),9-12 peripheral vascular disease,13 and stroke.14,15
Muir et al16 proposed three hypotheses regarding the rela-
tion between CRP concentration and stroke: CRP concen-
tration may reflect the severity of stroke, correlating with
the degree of inflammation as a direct consequence of
cerebral infarction; CRP concentration may indicate unsta-
ble atherosclerotic plaque; and CRP concentration may
increase as a consequence of complications secondary to
stroke occurring at the time of blood sample collection.
Emerging evidence suggests that CRP may contribute
to inflammation in atheroma and be actively involved in
early atherogenesis. CRP accumulates in macrophage-rich
regions of the atherosclerotic lesion and regulates proin-
flammatory cytokine secretion by these cells. Furthermore,
it induces secretion of monocyte tissue factor, a potent
activator of the extrinsic coagulation cascade that is consid-
ered to have an important role in atherosclerosis. Monocyte
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tissue factor is expressed on macrophages in atherosclerotic
plaque, and may contribute to acute thrombotic events
associated with plaque rupture in unstable syndromes.17,18
The purpose of this study was to investigate the rela-
tions among serum CRP concentrations, morphologic
characteristics (stable or unstable) and types of cells present
in atherosclerotic plaque, and neurologic symptoms in
patients with more than 70% carotid stenosis undergoing
carotid surgery. Determination of biologic parameters that
indicate the unstable nature of carotid plaque may be useful
in selection of high-risk cohorts in this population.
PATIENTS AND METHODS
Patients. Between May 2000 and April 2001, 72 pa-
tients with greater than 70% carotid stenosis were admitted
to our center for carotid thromboendarterectomy. In-
formed consent was obtained from all patients before par-
ticipation in the study. All procedures were approved by the
local human ethics committee. The protocol used for later
data analysis was as follows: collection of clinical and para-
clinical data, blood sample collection for high-sensitivity
CRP (hs-CRP) analysis, performance of carotid surgery,
and preservation of carotid plaque for histologic analysis
and immunohistochemistry. We excluded patients with
recent clinical infection, patients with major renal, hepatic,
or malignant disease, patients who had undergone surgery
or sustained major trauma in the previous month, and
patients with signs and clinical evidence of nosocomial
infection. In five patients serum samples were insufficient to
perform hs-CRP determination, and in five others process-
ing of the carotid specimens was inadequate. Thus the final
number of patients included was 62.
The study population included 57 men and 5 women,
with age range from 42 to 83 years (mean, 67.1  9.2
years); 36 patients had a previous neurologic event, and 26
had no neurologic symptoms. In addition to the universal
epidemiologic variables (eg, age and gender), the protocol
included the following classic cardiovascular risk factors:
hypertension, defined as systolic blood pressure 140 mm
Hg or higher or diastolic blood pressure 90 mm Hg or
higher, or current use of antihypertensive medication; dia-
betes mellitus, defined as glycosylated hemoglobin A1c
concentration greater than 5.8% or current use of hypogly-
cemic agents; hypercholesterolemia, defined as total cho-
lesterol concentration 220 mg/dL or greater or current use
of lipid-lowering agents; and smoking, defined as current
smoking or cessation of smoking less than 1 month before
entering the study. Furthermore, we investigated the pres-
ence of concomitant cardiovascular disease, including pe-
ripheral vascular disease and ischemic heart disease, treat-
ment with anti-aggregant agents and lipid-lowering drugs,
and interval between the neurologic event and blood col-
lection. North American Symptomatic Carotid Endarterec-
tomy Trial criteria19 were used to classify patients as neu-
rologically symptomatic or asymptomatic. Degree of
carotid stenosis was determined with echo-Doppler scan-
ning (Philips SD800) of the supra-aortic trunk in all pa-
tients. In patients with greater than 70% stenosis on one
side and greater than 50% stenosis on the other side,
contralateral carotid occlusion, or low confidence in the
ultrasound examination, arteriography was additionally
performed.20 Brain parenchyma study was carried out with
computed tomography (CT) in the earlier cases and mag-
netic resonance imaging (MRI).
Measurement of circulating hs-CRP concentration.
Blood samples were collected 48 hours before surgery, and
serum hs-CRP concentrations were determined with neph-
elometry (nephelometer analyzer; Behring, Marburg, Ger-
many), with reagents from the same manufacturer. The
cutoff point above which levels of this marker were consid-
ered pathologic was 10 mg/L.
Histopathologic analysis. Carotid endarterectomy
was performed in a conventional series of patients with
conventional surgical techniques. In brief, the carotid ar-
tery was incised and the plaque removed from within the
lumen as a single specimen. For histopathologic analysis,
the surgical specimen was fixed in 10% formalin, decalcified
with ethylenediamine tetraacetic acid (EDTA; Surgipath
Medical Industries, Richmond, Ill) for 4 hours, cut trans-
versally in 2 mm blocks, processed, and embedded in
paraffin. The blocks were sectioned at 4 m and stained
with hematoxylin-eosin stain, van Gieson stain for elastic
fibers, and Masson trichrome stain. After the specimens
were prepared for histologic analysis, they were examined
by a pathologist blinded to the patient’s clinical status and
CRP concentration, with an optic microscope (Dialux
20EB, Leitz, Germany).
Morphologic characteristics of the carotid plaque were
established according to the classification of the American
Heart Association (AHA) for advanced lesions.21 Lesions
referred to as stable in this study are AHA type V, charac-
terized by fibrous conjunctive tissue together with extracel-
lular lipids and laminated acellular collagen, and no evi-
dence of endothelial disruption; lesions referred to as
complicated or unstable are AHA type VI, characterized by
ulceration (disruption of the endothelial surface) or recent
intraplaque hemorrhage consisting of diffuse blood (poly-
morphonuclear cell infiltrate and intact red blood cells) in
the subendothelial space. None of the plaque studied was
AHA types I to IV.
Immunohistochemistry. For immunohistochemical
study of tissue, the thin paraffin-embedded sections were
deparaffinized in xylene, rehydrated through graded alco-
hols, and preincubated in 10% hydrogen peroxide for 10
minutes. Antigen unmasking was performed at high tem-
perature and pressure. The samples were then incubated
with specific antibodies for macrophages, T lymphocytes,
and activated T lymphocytes for 60 minutes at room tem-
perature. The primary antibodies (Dako, Cambridge, En-
gland) were monoclonal for macrophages (CD68) and
activated T lymphocytes (HLA-DR), and polyclonal for T
lymphocytes (CD3). Subsequently, samples were incu-
bated with biotin-labeled secondary antibodies (Dako
Duet; Dako). Diaminobenzidine was used for develop-
ment. Finally, the blocks were stained with hematoxylin-
eosin for contrast, and examined with an optic microscope.
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Differential cell count was performed with a standard
morphometry method: random choice of 10 fields for each
preparation, and cell count for each type of cell in each field.
Results are expressed as number of cells per 10 fields.
Statistical analysis. Statistical analysis of the data was
performed with SPSS for Windows, version 10.0 (SPSS,
Chicago, Ill). The categorical variables were described in
frequencies. Because they did not follow a normal distribu-
tion, CRP values and cell counts were described with the
median as central measurement and the range as the mea-
sure of dispersion. Associations were considered statistically
significant at P  .05. The 2 test was used to establish
associations among categorical variables, and the Mann-
Whitney U test was used to assess intergroup differences for
continuous variables that did not follow a normal distribu-
tion. Comparisons between quantitative variables were per-
formed with the Spearman correlation coefficient. A re-
ceiver operator characteristic curve was used to establish the
value for macrophage number associated with unstable
plaque. Multivariate analysis was carried out by elaborating
a logistic regression model with the forward stepwise
method.
RESULTS
The prevalence of epidemiologic variables in neurolog-
ically symptomatic and asymptomatic patients is repre-
sented in Table I. Among patients with symptoms at pre-
sentation (n  36), 23 patients (63.8%) had transient
ischemic attack (TIA), which was retinal in 7 patients
(30.4%) and hemispheric in 16 patients (69.5%), and 13
patients (36.1%) had stroke. Echo-Doppler scanning of the
supra-aortic trunk was performed in all patients, to establish
the degree of stenosis, and in 24 patients (39.2%) cerebral
angiography was also indicated. To study the brain paren-
chyma, CT was performed in 48 patients (77.4%) and MRI
in 14 patients (22.6%). Forty-eight percent of these studies
were interpreted as normal; 11.8% of patients had cortical
atrophy, and 40.2% had ischemic areas corresponding to
the region of study. No patients had a silent infarction.
At histologic analysis 53.2% of plaque was classified as
unstable and 46.7% as stable. Regarding differential cell
count, in both types of plaque the most frequently encoun-
tered cells were macrophages, followed by T lymphocytes
and activated T lymphocytes. A median of 19 macrophages
per 10 fields (range, 4-45) was found in unstable plaque,
and 4 macrophages per 10 fields (range, 1-6) was found in
stable plaque. T lymphocyte count was 5 cells per 10 fields
(range, 1-12) in unstable plaque and 1 cell per 10 fields
(range, 0-2) in stable plaque. Activated T lymphocytes
presented a median of 2 cells per 10 fields (range, 0-6) in
unstable plaque and 0 cells per 10 fields (range, 0-1) in
stable plaque. Differences between the two groups were
statistically significant (P  .001). Unstable plaque was
significantly associated with neurologic symptoms (P 
.01).
Median serum hs-CRP concentration was 7.6 mg/L
(range, 0.3-165 mg/L). The prevalence of increase of this
parameter over the cutoff point was 46.8%.
Study of the relation between serum hs-CRP concen-
tration and presence or absence of neurologic symptoms
showed statistically significant differences (P  .001).
Eighty-one percent of patients with a previous neurologic
event had hs-CRP concentrations higher than 10 mg/L
(median, 29.6 mg/L; range, 1.8-165 mg/L), whereas no
patients without neurologic symptoms had hs-CRP con-
centration over the cutoff (median, 3.2 mg/L; range, 0.3-
8.3 mg/L). Median hs-CRP values were 24.7 mg/L
(range, 1.8-165 mg/L) in patients with clinical manifesta-
tions of TIA, and 41.2 mg/L (range, 3.1-100 mg/L) in
patients with stroke; differences between these groups were
not significant.
Mean interval between the ischemic event and hs-CRP
measurement was 6.14 weeks (SD, 3.55 weeks). We ob-
served that the longer the interval since the cerebral isch-
emic event, the higher the levels of hs-CRP. Elevated
hs-CRP concentration (median of 27.1 mg/L, range of
1.8-165 mg/L for unstable plaque vs median of 4.1 mg/L,
Table I. Clinical and epidemiologic characteristics of study population
Symptomatic (n  36) Asymptomatic (n  26)
Pn % n %
Age (y) NS
Median 66.5 68.5
Range 42-79 54-83
Gender (male) 33 91.6 24 92.3 NS
Body mass index (kg/m2) NS
Median 24 23
Range 19-39 19-29
Hypertension 14 38.9 15 57.7 NS
Smoking 11 30.6 11 42.3 NS
Hypercholesterolemia 12 33.3 10 38.5 NS
Diabetes mellitus 9 25 11 42.3 NS
Lipid-lowering drugs 4 11.1 8 30.8 NS
Antiaggregant therapy 19 52.7 7 26.9 NS
Peripheral vascular disease 9 25 4 15.4 NS
Ischemic heart disease 6 16.6 4 15.3 NS
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range of 0.3-36 mg/L for stable plaque) was significantly
associated with the presence of unstable plaques (P .001;
Fig 1). Regarding cell type, we found that the greater the
number of macrophages in the plaque, the higher the levels
of hs-CRP (Spearman   0.61; P  .001; Fig 2). We also
found a significant association between the presence of T
lymphocytes and elevated hs-CRP (Spearman   0.52; P
 .001).
Mean hs-CRP concentration was 7.4 mg/L (range,
0.4-88.8 mg/L) in patients who smoked (n  22), and
10.1 mg/L (range, 0.3-165 mg/L) in nonsmokers (n 
40); differences were not significant (P  .68). CRP con-
centration was greater than 10 mg/L in 40.9% (n  9) of
smokers and in 50% (n  20) of nonsmokers; differences
were not significant (P  .49).
No significant difference in CRP concentration was
found according to sex. Mean CRP concentration was 7.5
mg/L (range, 0.9-165 mg/L) in men, and 25.3 mg/L
(range, 0.3-100 mg/L) in women (P  .84). However,
this absence of differences may be due to the small number
of women (n  5) in the study.
CRP concentration was somewhat lower in the group
of patients taking statin drugs (mean, 5.5 mg/L; range,
0.4-100 mg/L) compared with patients not taking these
drugs (mean, 7.7 mg/L; range, 0.3-165 mg/L), although
differences were not significant (P  .95). In the 33 pa-
tients with unstable plaque, there were no significant dif-
ferences in CRP concentration between the 7 patients
receiving statin drugs and the 26 patients who were not
receiving this medication: 33.9 mg/L (range, 2.8-100
mg/L) versus 26.2 mg/L (range, 1.8-165 mg/L; P 
.68). In patients taking statin drugs, macrophage count in
plaque was 18 cells per 10 fields (range, 5-45), compared
with 20 cells per 10 fields (range, 4-36) in patients not
taking this medication (P  .72). Statistical differences
were found, however, in T-lymphocyte count; the patients
receiving statins had fewer T lymphocytes: 4.5 cells per 10
fields (range, 1-8) in patients taking statin drugs compared
with 6 cells per 10 fields (range, 2-12) in patients not
receiving this medication (P  .02).
At logistic regression analysis the two variables that
were independently associated with unstable plaque were
previous neurologic event and presence of macrophages in
plaque (Tables II, III).
DISCUSSION
The results of this study show a clear association be-
tween the inflammatory process and phenomena of carotid
plaque complications. Plaque classified as unstable or com-
plicated (ie, with endothelial ulceration or recent in-
traplaque hemorrhage) showed a significantly greater den-
sity of cells implicated in cellular immunity (macrophages,
T lymphocytes, activated T lymphocytes) compared with
plaque classified as stable (ie, fibrous surface or old inter-
plaque hemorrhage). Among the three cell types, the most
frequent were macrophages, followed by T lymphocytes
and activated T lymphocytes. Similar findings have been
reported by van der Wal et al,2 Carr et al,3 and Moreno et
al.22 These results are biologically plausible, considering
that macrophages are present in all phases of atherosclero-
sis, whereas T lymphocytes and activated T lymphocytes
appear more frequently in later phases. Several growth
factors, such as transforming growth factor beta, are impli-
cated in the synthesis of collagen in the fibrous surface of
Fig 1. C-reactive protein concentration relative to stable and
unstable plaque.
Fig 2. C-reactive protein concentration relative to number of
macrophages in plaque.
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the plaque, and other factors, such as interferon (IFN-),
alter collagen synthesis in smooth muscle cells and inhibit
their proliferation.23 Only activated T lymphocytes can
produce IFN- and when these cells are chronically acti-
vated, IFN- alters repair of collagen matrix in the plaques.
Moreover, unstable plaque expresses metalloproteinases,
which break down collagen and other extracellular matrix
components of the plaque, thereby further “destabilizing”
them.24
In parallel, we noted that patients with ulcerated plaque
or histologic signs of recent intraplaque hemorrhage were
those with past neurologic symptoms corresponding to the
carotid region studied, with TIA the most frequently oc-
curring clinical form. These results are in keeping with
those reported by Zukowski et al25 and Avril et al.26 Plaque
ulceration is probably the most common histologic finding
in patients with an ischemic cerebral deficit, which supports
the emboligenic theory to explain production of the isch-
emic event.
In the present study, elevated hs-CRP concentration
was related to a history of stroke, as demonstrated by
Rekasem,27 with unstable plaque, and with increased mac-
rophages in the plaque. We believe that increased hs-CRP is
not a direct consequence of the ischemic injury. The mean
interval between the stroke and hs-CRP determination was
6.14 weeks. It seems logical that if the increase in hs-CRP
was a result of stroke, the high levels of the protein would
drop over time; rather, we found that the longer the
interval, the greater the increase. Moreover, as many as 25%
of patients with stroke have normal CRP concentration
after the ischemic event, as demonstrated by Di Napoli et
al.15 In addition, we found no significant differences in
CRP concentration according to severity of the neurologic
event (stroke vs TIA), a result in keeping with the findings
of Canova et al,28 who showed that CRP concentration in
138 patients with neurologic deficit was not significantly
different among five clinical categories: TIA, reversible
neurologic deficit, complete stroke and recovery, stroke
without recovery, and cerebral hemorrhage.28
Patients with unstable plaque had significantly higher
hs-CRP concentration compared with patients with stable
plaque, and unstable plaque exhibited a significantly higher
Table II. Association between cardiovascular risk factors, plaque structure, neurologic events, and CRP concentration
Unstable (n  33) Stable (n  29)
Pn % n %
Age (y) NS
Median 66 67
Range 48-83 42-79
Gender (male) 30 90.9 27 93.1 NS
Body mass index (kg/m2) 25 19-40 23 19-29 NS
Hypertension 17 51.5 12 41.4 NS
Diabetes mellitus 13 39.4 7 24.1 NS
Smoker 13 39.4 9 31 NS
Dyslipidemia 12 36.4 10 34.5 NS
Lipid-lowering drugs 7 21.2 5 17.2 NS
Antiaggregant therapy 14 42.4 12 41.4 NS
Peripheral vascular disease 7 21.2 6 20.7 NS
Ischemic heart disease 5 15.2 5 17.2 NS
Cerebral infarction 14 42.4 11 33.3 NS
Neurologic event 27 81.8 9 31 .001
Macrophage count (cells/10 fields) .001
Median 19 4
Range 4-45 1-6
High-sensitivity C-reactive protein
(mg/L)
.001
Median 27.1 4.1
Range 1.8-1.65 0.03-560
Table III. Factors associated with unstable plaque in bivariate analysis and logistic regression model
Bivariate analysis Logistic regression
OR (95% CI) P OR (95% CI) P
Macrophage count* 24 (6.82-84.43) .0001 31.93 (5.90-172.71) .0001
Neurologic event 17.13 (4.85-60.46) .0001 23.52 (4.05-136.36) .0004
hs-CRP† 15.91 (4.93-51.38) .0001
hs-CRP, High-sensitivity C-reactive protein; OR, odds ratio; CI, confidence interval.
*Macrophage number (  5; 	5) was established from the receiver operating characteristic curve.
†Cut-off for abnormal hs-CRP was 10 mg/L.
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number of macrophages and T lymphocytes than did stable
plaque. Furthermore, as macrophage and T lymphocyte
counts in the plaque increased, CRP concentration in-
creased. We also observed a positive correlation between
macrophage count and T lymphocyte count; that is, in
plaque with more than 10 macrophages per 10 fields the
number of T lymphocytes observed increased along with
the number of macrophages, and this finding was seen
more frequently in areas of the plaque with ulceration.
A weaker correlation was found between the presence
of macrophages in plaque and increased CRP concentra-
tion in asymptomatic disease than in symptomatic disease.
Nevertheless, the subgroup of patients without symptoms
and elevated CRP concentration might also be considered a
group at risk, because elevated CRP concentration indi-
cates the presence of macrophages in plaque, a factor linked
with instability.
The correlation between macrophages and CRP con-
centration could explain a direct effect of the protein on
atherosclerotic lesions, as has been suggested by Nakagomi
et al.17 These authors proposed that CRP may alter clotting
status through induction of monocyte tissue factor, which
may be a key mediator of thrombosis in atherosclerosis;
circulating tissue factor is detected in patients with unstable
angina, and high levels are expressed on macrophages in
unstable plaque. Others, such as Torzeuski et al,18 have
suggested a functional role of CRP in monocyte recruit-
ment, on the basis of results indicating that CRP may
promote progression of early atherosclerotic lesions. In a
study using in situ hybridization, Yasojima et al29 detected
intense signals for CRP in macrophages in atherosclerotic
plaque, and postulated that CRP may be a precursor to
thrombotic events by means of a self-sustaining autotoxic
mechanism operant within the plaque.
Another recent work relating CRP concentration with
plaque instability, performed by Virmani et al,30 defines the
precursor lesion of plaque rupture as thin-cap fibroathe-
roma (TCFA). Morphologically, TCFA has a necrotic core
with an overlying thin fibrous cap (65 mm) consisting of
type I collagen infiltrated by macrophages. These lesions
are most frequent in the coronary tree of patients dying of
acute myocardial infarction, and are least frequent in those
with plaque erosion. TCFA are more common in patients
with high serum total cholesterol and a high total choles-
terol to high-density lipoprotein ratio, in women older than
50 years, and in patients with elevated hs-CRP concentra-
tion. There is therefore increasing evidence pointing to an
active role of CRP in atherosclerotic lesion formation.
Recent studies have evidenced differences in CRP levels
according to sex. Wang et al31 concluded that there is a
graded association between CRP and carotid atherosclero-
sis in women but not in men. Ridker et al32 studied 28,263
apparently healthy postmenopausal women over a mean
follow-up of 3 years, to assess risk for cardiovascular events
associated with baseline levels of markers of inflammation.
Of the 12 markers measured, CRP was the strongest uni-
variate predictor of risk for cardiovascular events; the rela-
tive risk for events in women in the highest as compared
with the lowest quartile for this marker was 4.4 (95%
confidence interval, 2.2-8.9). In contrast, no significant
differences in CRP concentration according to sex were
found in our series: mean CRP level was 7.5 mg/L (range,
0.9-165 mg/L) in men and 25.3 mg/L (range, 0.3-100
mg/L) in women (P  .84); nonetheless, this absence of
significant difference may be due to the small number of
women in the study.
Recent studies have also demonstrated that inflamma-
tory markers can be increased in smokers. Thus Magyar et
al33 recommended taking into account this potentially
confounding factor in studies of atherosclerosis. We found
no relation between smoking and CRP concentration in
the present study.
It has also been observed that statin drugs can reduce
inflammatory phenomena and contribute to stabilization of
plaque. Analysis of this factor in our series showed no
significant differences between patients with unstable
plaque taking statin drugs and those not taking them, in
terms of CRP concentration and macrophage count in
plaque. There were, however, differences with regard to T
lymphocyte count. Patients taking statin drugs had fewer T
lymphocytes in plaque than those not receiving these
drugs.
This study has some limitations. Although CRP is a
sensitive marker of inflammation, it has low specificity.
Many of its functions are known, but the importance of
these functions in atherosclerotic plaque has not been
completely defined. Moreover, CRP values show consider-
able intraindividual variability,34 and it is not known
whether factors such as age, smoking habit, sex, meno-
pause, or acute disease may modify levels of this plasma
protein. Longitudinal studies are needed to determine
whether there is an association between elevated CRP
concentration and progression or complication of athero-
sclerosis.
In summary, elevated CRP concentration was found in
patients with carotid stenosis with a history of neurologic
symptoms and in patients with complicated carotid plaque
showing a marked increase in inflammatory phenomena at
histologic analysis and immunohistochemistry. Although
clinical assessment is essential for estimating stroke risk, the
future use of inflammatory markers such as CRP, together
with conventional tests, may help in identification of per-
sons at risk among patients with carotid stenosis. It is likely
that treatment to decrease the inflammatory phenomena
occurring in atherosclerosis would facilitate control of car-
diovascular events. This would no doubt contribute to
improving the quality of management of one of the major
health problems in the western world, that is, ischemic
stroke.
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